| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 360.53% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 08/14/2023 | 360.53% | HC Wainwright & Co. | $6 → $7 | Maintains | Buy |
| 08/01/2023 | 294.74% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 07/20/2023 | 294.74% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 04/10/2023 | 294.74% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 09/26/2022 | 294.74% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 09/23/2022 | 426.32% | Evercore ISI Group | $2 → $8 | Upgrades | In-Line → Outperform |
| 08/15/2022 | 360.53% | HC Wainwright & Co. | $10 → $7 | Maintains | Buy |
| 05/23/2022 | 557.89% | HC Wainwright & Co. | $37 → $10 | Maintains | Buy |
| 05/20/2022 | 31.58% | Berenberg | → $2 | Downgrades | Buy → Hold |
| 05/17/2022 | 228.95% | Cantor Fitzgerald | $27 → $5 | Maintains | Overweight |
| 05/04/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 05/04/2022 | 31.58% | Evercore ISI Group | $40 → $2 | Downgrades | Outperform → In-Line |
| 04/18/2022 | 2334.21% | HC Wainwright & Co. | $43 → $37 | Maintains | Buy |
| 03/21/2022 | 2728.95% | HC Wainwright & Co. | $40 → $43 | Maintains | Buy |
| 10/01/2021 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 01/22/2021 | 2531.58% | HC Wainwright & Co. | $33 → $40 | Maintains | Buy |
| 12/16/2020 | 2992.11% | Berenberg | → $47 | Initiates Coverage On | → Buy |
| 11/23/2020 | 2071.05% | HC Wainwright & Co. | $28 → $33 | Maintains | Buy |
| 09/29/2020 | 4505.26% | Evercore ISI Group | → $70 | Initiates Coverage On | → Outperform |
| 05/11/2020 | 1742.11% | HC Wainwright & Co. | $25 → $28 | Reiterates | → Buy |
| 03/17/2020 | 1281.58% | Stifel | $22 → $21 | Maintains | Buy |
| 11/05/2019 | 2202.63% | HC Wainwright & Co. | $28 → $35 | Maintains | Buy |
| 09/09/2019 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 09/04/2019 | 1742.11% | HC Wainwright & Co. | → $28 | Assumes | → Buy |
| 10/16/2018 | 492.11% | B of A Securities | $19 → $9 | Downgrades | Neutral → Underperform |
What is the target price for Spero Therapeutics (SPRO)?
The latest price target for Spero Therapeutics (NASDAQ: SPRO) was reported by HC Wainwright & Co. on September 5, 2023. The analyst firm set a price target for $7.00 expecting SPRO to rise to within 12 months (a possible 360.53% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Spero Therapeutics (SPRO)?
The latest analyst rating for Spero Therapeutics (NASDAQ: SPRO) was provided by HC Wainwright & Co., and Spero Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Spero Therapeutics (SPRO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spero Therapeutics was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
Is the Analyst Rating Spero Therapeutics (SPRO) correct?
While ratings are subjective and will change, the latest Spero Therapeutics (SPRO) rating was a reiterated with a price target of $0.00 to $7.00. The current price Spero Therapeutics (SPRO) is trading at is $1.52, which is within the analyst's predicted range.